Five-year Survival Rate For Nivolumab-treated Advanced Lung Cancer Patients Much Higher Than Historical Rate
Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with…
Browsing: Opdivo
Combination of ground-breaking treatments offer powerful new path for blood cancer therapies
Researchers have identified for the first time how a new class of epigenetic drug engages with…